Arlington Capital Partners Announces the Sale of Avalign Technologies

WASHINGTON, DC, January 3, 2019 – Arlington Capital Partners (“Arlington Capital”), a Washington, DC-based private equity firm, announced today the sale of Avalign Technologies (“Avalign” or the “Company”) to Linden Capital Partners. Avalign, based in Bannockburn, IL, is a leading provider of proprietary coatings and full-service precision manufacturing solutions to the orthopedic medical device and specialty surgical markets. Avalign offers its OEM partners a broad portfolio of manufacturing solutions and extensive engineering design, development, and project management capabilities from concept to launch.

Matt Altman, a Managing Partner at Arlington Capital said, “Our successful partnership with Avalign’s founding management team enabled the Company to expand its proprietary technology offering, capitalize on strong macro trends in the orthopedic market and serve as a leading consolidator in the fragmented outsourced medical device manufacturing market. The Avalign transaction represents another example of Arlington’s thematic approach to investing in the pharmaceutical and medical device industries. We have very much enjoyed the opportunity to partner with the Avalign management team and look forward to watching Avalign’s continued success in the future.”

Forrest Whittaker, CEO of Avalign, stated, “Our partnership with Arlington has been a great success for the Company and the management team. Arlington Capital’s deep expertise and impressive track record in healthcare and precision manufacturing provided an ideal partnership to help us achieve our goals. Arlington invested significant capital to support our organic growth and to complete several valuable acquisitions which were instrumental to Avalign’s growth.”

Malcolm Little, a Principal at Arlington Capital said, “Since our initial investment, Avalign has nearly doubled in size as strong organic growth has been bolstered by several strategic acquisitions.  We are proud to have supported the Company through this transformation, adding capacity and bringing new technologies into Avalign’s portfolio in partnership with the outstanding Avalign management team.”

William Blair and Harris Williams served as financial advisors to Arlington and Avalign. Greenberg Traurig served as legal advisor to Arlington and Avalign.


About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private equity firm that has managed $2.2 billion of committed capital via four investment funds. Arlington focuses on middle market investment opportunities in growth industries, including: healthcare, aerospace/defense, government services and technology, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enables Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company’s position as leading competitors in their field. For more information:


About Avalign Technologies

Avalign is a leading provider of proprietary coatings and full-service precision manufacturing solutions for implants, surgical instruments, cutting instruments, and delivery systems to the orthopedic medical device and specialty surgical markets. The Company provides its patented porous coating technology, as well as a full suite of manufacturing technologies including machining, metal injection molding, finishing and assembly to medical device OEMs from concept to launch. Avalign has an established reputation for consistent and sophisticated quality systems, flexible capacity capabilities, innovative proprietary manufacturing technologies, an unmatched product offering, and superior customer service.



Matt Altman and Malcolm Little

Arlington Capital Partners

5425 Wisconsin Avenue, Suite 200

Chevy Chase, MD 20815

(202) 337-7500

SOURCE: Arlington Capital Partners